COMP <GO>
ZYME vs SRPT // OPERATING MARGIN
Zymeworks Inc. (NASDAQ) VS. Sarepta Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ZYME 5
— SRPT 3
▲ OPERATING MARGIN LEADER: SRPT
LAST: $28.71 (-0.66%) • MKT CAP: $2.02B
operating-margins
-60.00%
LAST: $19.23 (-0.47%) • MKT CAP: $2.03B
operating-margins
-37.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZYME VS. SRPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZYME | SRPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.20% | -35.00% | +2.80 | ZYME | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.71% | -15.14% | +13.43 | ZYME | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | -37.50% | -22.50 | SRPT | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -38.30% | -21.70 | SRPT | /net-margins <GO> |
| Revenue Growth (YoY) | 38.90% | 4.30% | +34.60 | ZYME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.85 | 0.20 | +11.65 | ZYME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 51.2 | +9.14 | ZYME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.02B | $2.03B | -$7.9M | SRPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZYME REV | SRPT REV | ZYME GROSS % | SRPT GROSS % | ZYME FCF | SRPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $106.0M | $1.86B | — | 98.0% | -$34.5M | -$307.5M |
| FY 2024 | $76.3M | $1.79B | — | — | -$112.0M | -$342.7M |
| FY 2023 | $76.0M | $1.14B | — | — | -$118.3M | -$501.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZYME // BETA —
SRPT // BETA —